BenevolentAI
Bruce Campbell Bsc, PhD Chem FRSC has more than 45 years of drug development experience and has developed 13 drugs or vaccines in a wide range of indications which have made it to the market. Formerly R and D Director at Servier (UK) , Senior VP of Research and Development at Neurocrine Biosciences, Inc (US) , Chief Scientific Officer at IP2IPO ( IPGroup), Founder, Chairman and Head of Development for Proximagen Ltd , he currently acts as a consultant to various pharmaceutical companies in Europe and the USA. In addition, he has been on the board of Proximagen , IPGroup , hVivo, Modern Biosciences, Synairgen and IQur and has been a director and European Chairman of the Drug Information Association, and a member of the European ICH Safety Working Party helping to write ICH safety guidances He is a visiting Professor in Pharmacology at King’s College, London and written more than 100 papers involving all aspects of drug development.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
BenevolentAI
8 followers
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.